(DIM) Sartorius Stedim Biotech - Overview
Stock: Bioreactors, Filtration, Consumables, Analytics, Software
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.38% |
| Yield on Cost 5y | 0.18% |
| Yield CAGR 5y | 0.37% |
| Payout Consistency | 84.1% |
| Payout Ratio | 25.5% |
| Risk 5d forecast | |
|---|---|
| Volatility | 47.9% |
| Relative Tail Risk | -19.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.42 |
| Alpha | -21.73 |
| Character TTM | |
|---|---|
| Beta | 0.165 |
| Beta Downside | 0.354 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.13% |
| CAGR/Max DD | -0.31 |
Description: DIM Sartorius Stedim Biotech December 19, 2025
Sartorius Stedim Biotech SA (ticker DIM) designs, manufactures, and sells a broad portfolio of bioprocessing instruments and consumables-including cell culture media, bioreactors, chromatography systems, and data-analytics software-that serve biopharmaceutical manufacturers, vaccine producers, and R&D labs worldwide.
Key performance indicators from the latest fiscal year show a 12 % YoY revenue increase to €2.1 bn, driven by strong demand for single-use bioreactors and automation solutions; operating margin expanded to 14 % as the company leveraged scale in its fluid-management and analytics offerings. The sector’s secular growth is underpinned by a projected 9 % CAGR in global biologics sales through 2028, with cell-and-gene therapies representing a primary catalyst for higher-value equipment spend.
The firm recently deepened its geographic reach through a partnership with Bio Usawa Biotechnology in Sub-Saharan Africa, targeting monoclonal-antibody production for oncology, diabetic eye disease, infectious, and autoimmune indications-an initiative that aligns with rising biotech activity in emerging markets and diversifies its customer base beyond traditional European and North-American hubs.
For a deeper dive into DIM’s valuation metrics and scenario analysis, the ValueRay research hub provides a concise, data-driven overview.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 263.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.94 > 1.0 |
| NWC/Revenue: 2.41% < 20% (prev 31.53%; Δ -29.13% < -1%) |
| CFO/TA 0.07 > 3% & CFO 590.0m > Net Income 263.9m |
| Net Debt (2.26b) to EBITDA (808.0m): 2.80 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.3m) vs 12m ago -0.79% < -2% |
| Gross Margin: 45.64% > 18% (prev 0.42%; Δ 4522 % > 0.5%) |
| Asset Turnover: 37.12% > 50% (prev 34.20%; Δ 2.91% > 0%) |
| Interest Coverage Ratio: 3.15 > 6 (EBITDA TTM 808.0m / Interest Expense TTM 156.8m) |
Altman Z'' 2.66
| A: 0.01 (Total Current Assets 1.38b - Total Current Liabilities 1.31b) / Total Assets 7.88b |
| B: 0.33 (Retained Earnings 2.59b / Total Assets 7.88b) |
| C: 0.06 (EBIT TTM 493.2m / Avg Total Assets 7.94b) |
| D: 1.06 (Book Value of Equity 4.04b / Total Liabilities 3.81b) |
| Altman-Z'' Score: 2.66 = A |
Beneish M -3.32
| DSRI: 0.73 (Receivables 249.2m/316.2m, Revenue 2.95b/2.74b) |
| GMI: 0.92 (GM 45.64% / 41.79%) |
| AQI: 0.99 (AQ_t 0.57 / AQ_t-1 0.58) |
| SGI: 1.08 (Revenue 2.95b / 2.74b) |
| TATA: -0.04 (NI 263.9m - CFO 590.0m) / TA 7.88b) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of DIM shares?
Over the past week, the price has changed by -5.52%, over one month by -19.50%, over three months by -6.57% and over the past year by -16.24%.
Is DIM a buy, sell or hold?
What are the forecasts/targets for the DIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 241.4 | 35.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 156.6 | -12% |
DIM Fundamental Data Overview February 03, 2026
P/E Trailing = 69.2279
P/E Forward = 36.4964
P/S = 6.2176
P/B = 4.6151
P/EG = 1.0389
Revenue TTM = 2.95b EUR
EBIT TTM = 493.2m EUR
EBITDA TTM = 808.0m EUR
Long Term Debt = 2.68b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 549.5m EUR (from shortTermDebt, last quarter)
Debt = 2.56b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.26b EUR (from netDebt column, last quarter)
Enterprise Value = 20.59b EUR (18.32b + Debt 2.56b - CCE 298.7m)
Interest Coverage Ratio = 3.15 (Ebit TTM 493.2m / Interest Expense TTM 156.8m)
EV/FCF = 88.01x (Enterprise Value 20.59b / FCF TTM 233.9m)
FCF Yield = 1.14% (FCF TTM 233.9m / Enterprise Value 20.59b)
FCF Margin = 7.94% (FCF TTM 233.9m / Revenue TTM 2.95b)
Net Margin = 8.96% (Net Income TTM 263.9m / Revenue TTM 2.95b)
Gross Margin = 45.64% ((Revenue TTM 2.95b - Cost of Revenue TTM 1.60b) / Revenue TTM)
Gross Margin QoQ = 46.39% (prev 46.27%)
Tobins Q-Ratio = 2.61 (Enterprise Value 20.59b / Total Assets 7.88b)
Interest Expense / Debt = 2.01% (Interest Expense 51.4m / Debt 2.56b)
Taxrate = 25.97% (22.7m / 87.4m)
NOPAT = 365.1m (EBIT 493.2m * (1 - 25.97%))
Current Ratio = 1.05 (Total Current Assets 1.38b / Total Current Liabilities 1.31b)
Debt / Equity = 0.64 (Debt 2.56b / totalStockholderEquity, last quarter 4.04b)
Debt / EBITDA = 2.80 (Net Debt 2.26b / EBITDA 808.0m)
Debt / FCF = 9.68 (Net Debt 2.26b / FCF TTM 233.9m)
Total Stockholder Equity = 4.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.32% (Net Income 263.9m / Total Assets 7.88b)
RoE = 6.60% (Net Income TTM 263.9m / Total Stockholder Equity 4.00b)
RoCE = 7.38% (EBIT 493.2m / Capital Employed (Equity 4.00b + L.T.Debt 2.68b))
RoIC = 5.41% (NOPAT 365.1m / Invested Capital 6.74b)
WACC = 5.90% (E(18.32b)/V(20.88b) * Re(6.52%) + D(2.56b)/V(20.88b) * Rd(2.01%) * (1-Tc(0.26)))
Discount Rate = 6.52% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 2.75%
[DCF Debug] Terminal Value 85.55% ; FCFF base≈297.5m ; Y1≈276.1m ; Y5≈251.8m
Fair Price DCF = 54.57 (EV 7.57b - Net Debt 2.26b = Equity 5.31b / Shares 97.3m; r=5.90% [WACC]; 5y FCF grow -9.09% → 2.90% )
EPS Correlation: -74.16 | EPS CAGR: -17.57% | SUE: -0.10 | # QB: 0
Revenue Correlation: -57.92 | Revenue CAGR: -2.57% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.34 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=5.33 | Chg30d=+0.001 | Revisions Net=+1 | Growth EPS=+18.4% | Growth Revenue=+8.6%